Vertex Pharmaceuticals has secured two simultaneous US Food and Drug Administration (FDA) approvals for cystic fibrosis (CF ... application for VX-522, a product of the collaboration that is ...

The company is poised to expand its commercial presence with significant upcoming launches in the pain and cystic fibrosis ... Alyftrek and the potential of VX-522 could further solidify Vertex ...

Change in sweat chloride from week 16 to week 40 VX-770: 2.2 mEq/L ± 12.2 CF = cystic fibrosis; CFQ-R = Cystic Fibrosis Questionnaire-Revised; FEV 1 = forced expiratory volume in 1 second.

VX-522: The multiple ascending dose (MAD ... Vertex increased its estimates for the number of people with cystic fibrosis in the U.S., Europe, Australia, and Canada from approximately 92,000 ...